摘要
背景:鸟苷酸环化酶C(GC-C)受体是一种跨膜受体,主要在肠上皮细胞中表达,其被认为在消化道的稳态和功能中起主要作用。该受体的内源性配体是旁分泌激素尿鸟苷素和鸟苷素。在配体结合后,GC-C受体增加环磷酸鸟苷(cGMP)水平,调节多种关键细胞类型特异性过程,例如氯化物和碳酸氢盐分泌,上皮细胞生长,肠屏障完整性调节和内脏敏感性。有人提出,GC-C作为一种肠道肿瘤抑制剂可能阻止结直肠癌的发生和发展。实际上,配体表达的丧失是散发性结直肠癌发生中的普遍步骤。有趣的是,GC-C的作用不仅限于消化道,而且已扩展到其他一些系统,例如心血管系统,肾脏和中枢神经系统,其中它涉及肠 - 下丘脑内分泌轴调节食欲。 目的:在这篇综述中,我们总结了GC-C受体及其配体的生理学,重点介绍了新开发的药物,如利那洛肽,以及他们提出的扭转/预防受体所涉及疾病的作用。 结论:现有的数据表明尿鸟苷素和鸟苷素及其受体和胃肠道和肾脏疾病,结直肠癌,肥胖症,代谢综合征和精神障碍等病理过程之间存在关系。 GC受体调节中的最新药理学发展可能涉及对相关疾病治疗的进一步改进。
关键词: 鸟苷酸环化酶C,热稳定肠毒素,腹泻,肠易激综合征,便秘,结肠直肠癌,肥胖症,炎症性肠病。
Current Medicinal Chemistry
Title:Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology
Volume: 25 Issue: 16
关键词: 鸟苷酸环化酶C,热稳定肠毒素,腹泻,肠易激综合征,便秘,结肠直肠癌,肥胖症,炎症性肠病。
摘要: Background: Guanylate cyclase C (GC-C) receptor is a transmembrane receptor, predominantly expressed in intestinal epithelial cells, which is considered to play a main role in homeostasis and function of the digestive tract. The endogenous ligands for this receptor are the paracrine hormones uroguanylin and guanylin. Upon ligand binding, GC-C receptors increase cyclic guanosine monophosphate (cGMP) levels, regulating a variety of key cell-type specific processes such as chloride and bicarbonate secretion, epithelial cell growth, regulation of intestinal barrier integrity and visceral sensitivity. It has been suggested that GC-C acts as an intestinal tumor suppressor with the potential to prevent the initiation and progression of colorectal cancer. In fact, loss of ligand expression is a universal step in sporadic colorectal carcinogenesis. Interestingly, the role of GC-C is not limited to the digestive tract but it has been extended to several other systems such as the cardiovascular system, kidney, and the central nervous system, where it has been involved in a gut-hypothalamus endocrine axis regulating appetite.
Objetive: In this review we summarize the physiology of the GC-C receptor and its ligands, focusing on newly developed drugs like linaclotide, and their suggested role to reverse/prevent the diseases in which the receptor is involved.
Conclusion: Available data points toward a relationship between uroguanylin and guanylin and their receptor and pathological processes like gastrointestinal and renal disorders, colorectal cancer, obesity, metabolic syndrome and mental disorders among others. Recent pharmacological developments in the regulation of GC-receptor may involve further improvements in the treatment of relevant diseases.
Export Options
About this article
Cite this article as:
Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology, Current Medicinal Chemistry 2018; 25 (16) . https://dx.doi.org/10.2174/0929867325666171205150310
DOI https://dx.doi.org/10.2174/0929867325666171205150310 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Proline-Rich Peptides: Multifunctional Bioactive Molecules as New Potential Therapeutic Drugs
Current Protein & Peptide Science MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences Current and Future Applications of Probiotics
Current Nutrition & Food Science Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Tissue Elasticity Bridges Cancer Stem Cells to the Tumor Microenvironment Through microRNAs: Implications for a “Watch-and-Wait” Approach to Cancer
Current Stem Cell Research & Therapy Coagulation and Cancer Therapy: The Potential of Natural Compounds
Current Genomics Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence
Current Drug Targets Connecting A Tumor to the Environment
Current Pharmaceutical Design Use of Small-molecule Inhibitory Compound of PERK-dependent Signaling Pathway as a Promising Target-based Therapy for Colorectal Cancer
Current Cancer Drug Targets A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis
Current Cancer Drug Targets Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Editorial (Hot Topic: Anti-cancer Molecular Targets of Natural Products)
Current Cancer Drug Targets Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry